Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the inadequate medical management of the patients. The therapeutic approach for drug-resistant tuberc...

Resistance to antituberculosis drugs has been documented since the 1940s, when the first medicines for tuberculosis were introduced. Since the initiation in 1994 of a global project to monitor the development of drug-resistant tuberculosis, nearly 60% of all countries in the world have implemented surveillance activities. In the past 15 years, special surveys have been the most common approach ...

Multi-drug resistant (MDR) and extensively-drug (XDR) as a result of continuous use antibiotics encourage the development new antimycobacterial drugs. In this study, 13 flavonoid compounds from flamboyant leaf plant were studied for their inhibitory properties MtKasA, MtDprE, MtPank which are significant enzymes in Mycobacterium tuberculosis, well molecular docking, dynamics, prediction ADMET-d...

BACKGROUND Investigation of genetic heterogeneity and spoligotype-defined lineages of drug-resistant Mycobacterium tuberculosis clinical isolates collected during a three-year period in two university hospitals and National Tuberculosis Reference and Research Laboratory in Ankara, Turkey. METHODS AND FINDINGS A total of 95 drug-resistant M. tuberculosis isolates collected from three different...

Drug induced reversion of antibiotic resistance is a promising way to combat multidrug resistant infections. However, lacking knowledge of mechanisms of drug resistance reversion impedes employing this approach in medicinal therapies. Induction of antibiotic resistance reversion by a new anti-tuberculosis drug FS-1 has been reported. FS-1 was used in this work in combination with standard anti-...

We developed a DNA sequencing-based method to detect mutations in the genome of drug-resistant Mycobacterium tuberculosis. Drug resistance in M. tuberculosis is caused by mutations in restricted regions of the genome. Eight genome regions associated with drug resistance, including rpoB for rifampin (RIF), katG and the mabA (fabG1)-inhA promoter for isoniazid (INH), embB for ethambutol (EMB), pn...

Simplifying and shortening treatment for drug-sensitive tuberculosis and providing new treatment options for drug-resistant tuberculosis constitute two principal goals in the development of novel drugs for tuberculosis. Demonstration of clinical efficacy in drug-sensitive tuberculosis is challenging, given high success rates for existing regimens, concerns about substituting an investigational ...

There has been considerable interest in various analogues of antitubercular drugs particularly against multidrug and extensively drug resistant tuberculosis because mycobacterium species has developed resistant against available drugs. The currently used antitubercular also causes some serious toxic effects and also require long period of therapy for the treatment. Therefore, various new drugs ...

A cross-sectional descriptive study was carried out at a tuberculosis center, Yangon, Myanmar from October 2003 to July 2004 to analyze the drug susceptibility of new sputum smear positive pulmonary tuberculosis patients. A total of 202 Mycobacterium tuberculosis isolates were tested for resistance to isoniazid, streptomycin, rifampicin and ethambutol. Resistance to at least one anti-tuberculos...